Related Experiment Video
Updated: May 22, 2026
06:38
A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells
Published on: January 22, 2021
Decrease of CD44-positive cells correlates with tumor response to chemotherapy in patients with gastrointestinal
Vindhya Palagani1, Mona El Khatib, Till Krech
1Department of Internal Medicine I, Medical University Hospital, Otfried Mueller Str. 10, 72076 Tuebingen, Germany.
Anticancer Research
|May 18, 2012
Summary
CD44 expression monitoring can indicate chemotherapy effectiveness in gastrointestinal cancers. A decrease in CD44 levels correlates with positive patient response to treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- CD44 is a key cell surface molecule regulating proliferation, differentiation, migration, and angiogenesis.
- Its role in metastasized pancreatic, colorectal, and stomach cancers under palliative chemotherapy requires investigation.
Purpose of the Study:
- To explore the potential role of CD44 in patients with advanced gastrointestinal cancers undergoing palliative chemotherapy.
- To assess if CD44 expression can serve as a biomarker for treatment response.
Main Methods:
- CD44 expression was quantified using flow cytometry in blood samples from 15 patients.
- Correlations were analyzed between CD44 levels, CA19-9, and computed tomography findings.
Main Results:
- A significant correlation (p<0.05) was observed between decreased CD44 expression and tumor response.
- This correlation was assessed using tumor marker elevation and Response Evaluation Criteria in Solid Tumors (RECIST).
Conclusions:
- Changes in CD44 expression can be monitored during chemotherapy.
- A decrease in CD44 levels is linked to a positive patient response to treatment.
- CD44 detection is a valuable tool for monitoring chemotherapy response in gastrointestinal cancer patients.
